Drugs / HB-AS02
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial | ||||||
| Phase 3 | NCT00445185 | Mar 2007 → Jul 2009 | hepatitis B virus infection | Henogen | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT00480116 Comparator | Jan → Apr 2008 | hepatitis B virus infection | Henogen | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HB-AS02 | “HB-AS02 is an investigational adjuvanted hepatitis B virus (HBV) vaccine for potential use in patients with renal insufficiency and other immunocompromized individuals.” PMID 20523113 ↗ Jul 20101“Three doses of the investigational AS02(v)-adjuvanted hepatitis B virus (HBV) vaccine HB-AS02 have been shown to induce more rapid seroprotection” PMID 21892006 ↗ Sep 2011 |
| Modality | Vaccine | “investigational AS02(v)-adjuvanted hepatitis B virus (HBV) vaccine” PMID 21892006 ↗ Sep 2011 |
| Route | Intramuscular | “20 µg, IM, month 0 and 1” NCT00480116 ↗ |